Aptorum Group Ltd Class A

Aptorum Group Limited is a clinical-stage biopharmaceutical company that, through its subsidiaries, discovers, develops, and commercializes therapeutic products for oncology and infectious diseases. Its pipeline includes SACT-1, a repurposed drug candidate in Phase 1 trials for neuroblastoma and other cancers, and ALS-4, a repurposed small molecule in Phase 1 trials for bacterial infections such as Staphylococcus aureus, Mycobacterium tuberculosis, and Pseudomonas aeruginosa. The company also develops SACT-COV19 for coronavirus disease, SACT-2 and SACT-3, ALS-1 for bacterial infections including MRSA, and ALS-2/3 for gram-positive bacterial infections, all in preclinical trials. Formerly known as APTUS Holdings Limited, it changed its name to Aptorum Group Limited in October 2017, was incorporated in 2010, and is headquartered in London, the United Kingdom.